The University of California, Los Angeles (UCLA) has received a $120 million commitment to support the recently established California Institute for Immunology and Immunotherapy, positioning the university to establish research entities in Los Angeles focused on vaccine development and the microbiome.
Agribusiness giant Cargill is laying off thousands of its employees
A Delaware judge has reaffirmed her ruling that Tesla must revoke Elon Musk’s multibillion-dollar pay package
The number of job postings in the United States rebounded in October from a 3 1/2 year low in September, a sign that businesses are still seeking workers even though hiring has cooled
U.S. stocks tiptoed to more records after a quiet day of trading
Neurocrine Biosciences has achieved its hoped-for profile in a phase 2 schizophrenia trial, delivering its targeted level of efficacy with a lower rate of gastrointestinal adverse events than Bristol Myers Squibb’s KarXT. But the biotech only saw efficacy at the lowest dose—the three higher doses all failed.
Curi Bio is on the move. The Seattle-based company has signed a seven-year lease for a roomy, 13,942-square-foot space overlooking Puget Sound in Washington, with plans to move in by early 2025.
The FDA has cleared its first automated insulin pump for adults with Type 2 diabetes, with Insulet’s Omnipod 5 delivery system opening the door to a population of more than 6 million people.
Indivior is picking up a small molecule allosteric modulator designed to treat substance use disorder from Addex Therapeutics, providing the latter the chance to make up to $300 million in biobucks, plus royalties.
Flagship Pioneering and Pfizer have added Quotient into their 10-program partnership, inking a deal to discover new targets for two programs in cardiovascular and renal diseases.
Weekly Market Review – December 28, 2024
Edgewise’s stock jumps 50% on the back of safety data for potential heart disease rival to Camzyos
In 2 papers, researchers describe potential new neurodegenerative disease treatment approach
Aligos’ MASH prospect slashes liver fat in phase 2, but stock drops anyway
Vanda receives FDA rejection, issues fiery response against ‘conclusory’ refusal
Jury rules for Axonics in Medtronic’s long-running neuromodulation patent lawsuit
Achilles drops cell therapy program, braces for layoffs after missing ‘commercial viability’ goals
Basilea scores $268M BARDA funding deal to work on antifungals, antibiotics
From ‘science fiction to reality’: New George Church-founded biotech raises $75M for cell therapy platform
How the Stock Market Defied Expectations Again This Year, by the Numbers
